|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Developing novel drugs to treat renal and vascular diseases |
|
| Management |
| Timothy P. Noyes, President and CEO; Kimberly S. Bland, Ph.D., Senior Director of Research & Development; Steven K. Burke, M.D., Senior Vice President and Chief Medical Officer; Martha J. Carter, RAC, Senior Vice President of Regulatory Affairs and Quality Assurance; F. Nicholas Franano, M.D., Chief Scientific Officer; Joseph E. Tyler, Vice President of Manufacturing; William P. Whitaker, Esq., Vice President and General Counsel; Marco D. Wong, M.D., Ph.D., Physician-Scientist; Stephen J. Hoffman, Ph.D., M.D., General Partner, TVM Capital; David G. Lowe, Ph.D., Partner, Skyline Ventures; Brendan O'Leary, Ph.D., Principal, Prism VentureWorks; Timothy P. Noyes, President and CEO, Proteon Therapeutics, Inc.; F. Nicholas Franano, M.D., Chief Scientific Officer, Proteon Therapeutics, Inc. |
| |
|
|
| |
|
| Keywords |
| renal, kidney, vascular, stl |
|
|
|
| Description |
|
Proteon Therapeutics, Inc is a privately held biotechnology company developing novel, first-in-class pharmaceuticals to address the critical, rapidly expanding medical needs of patients with renal and vascular diseases. |
|
| Products / Services |
Proteon Therapeutics has two vasodilation drug candidates in pre-clinical testing, PRT-101 and PRT-201.
|
|
| Technology / Differentiation |
| Vascular remodeling is at the core of Proteon Therapeutics' proprietary vasodilation drug development program. This technology focuses on agents that modify the extracellular matrix of blood vessels, leading to immediate and persistent vessel enlargement. This local vasodilation improves the outcome of common vascular surgery procedures, leading to healthier patients and reduced treatment costs. |
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members